+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Competitor Landscape: Atopic Dermatitis

  • PDF Icon

    Report

  • 58 Pages
  • October 2018
  • Region: Global
  • GlobalData
  • ID: 4720456
Competitor Landscape: Atopic Dermatitis

Summary

"Competitor Landscape: Atopic Dermatitis", briefings contain evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, together with analysis of current & potential future product positioning.

Key Highlights from the report -
  • AT-502 is the second topical JAK inhibitor in development for atopic dermatitis behind ruxolitinib/ INCB018424, however is the only topical JAK inhibitor targeting moderate-to-severe AD.

  • Upadacitinib and baricitinib are competing to the first-in-class JAK inhibitor approved for AD, with upadacitinib likely approved a quarter before baricitinib in the US.

  • Data for PF-04965842's adolescent trial will likely be released in Q4 2019, and along with data from JADE Mono-1, will be the basis for filing in the adolescent patient population.


The report contains five key sections.

Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted view of the atopic dermatitis landscape.

Landscape Updates -
  • ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.

  • Timeline forecasts for each approved product’s lifecycle management initiatives.


Pipeline Landscape -
  • An overview of pipeline candidates, containing snapshots of current development status.

  • Expected drug-specific events & milestones until YE 2019.


Approved Product Landscape -
  • An overview of pipeline candidates, containing snapshots of current development status.

  • Expected drug-specific events & milestones until YE 2019.


Appendix -
  • Current early stage atopic dermatitis pipeline & candidate ‘Watch List’.

  • Timeline assumptions, including standard assumptions & drug-specific assumptions.


Scope
  • The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)

  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix

  • Forecasts are presented in pipeline forecast figures & detailed tables

  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.


Reasons to Buy
  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher

  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market

  • Reviews ongoing lifecycle management strategies for existing players in the market

  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Table of Contents

Introduction to Sociable Pharma’s ‘Competitor Landscape’
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Lifecycle Development
Pipeline Landscape
Pipeline Summary
Approved Product Development Landscape
Lifecycle Development
Appendix

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie

  • Aclaris

  • Akaal Pharma

  • Allergan

  • Amgen

  • Amorepacific Corporation

  • AnaptysBio

  • AntibioTx

  • AOBiome

  • Asana BioSciences

  • AstraZeneca

  • BioMimetix

  • Brickell Biotech

  • Celgene

  • Chugai

  • Connect Biopharma

  • Creabilis

  • Cutanea Life Sciences

  • Dermata Therapeutics

  • Dermavant Sciences

  • Dermira

  • DS Biopharma

  • Eli Lilly

  • Fountain Biopharma

  • Galapagos

  • Galderma

  • Galectin Therapeutics

  • Glenmark Pharma

  • GSK

  • Haus Bioceuticals

  • iCo Therapeutics

  • Immune Pharma

  • Incyte Corporation

  • Janssen

  • Japan Tobacco

  • Kang Stem Biotech

  • Kyowa Hakko Kirin

  • Leo Pharma

  • Medimetriks

  • MedImmune

  • Menlo Therapeutics

  • MorphoSys

  • NeRRe Therapeutics

  • Novan

  • Novartis

  • Otsuka

  • Pfizer

  • PurGenesis Technologies

  • Qurient

  • Ralexar Therapeutics

  • Realm Therapeutics

  • Regeneron

  • Roche

  • Roivant Sciences

  • Saniona

  • Sanofi

  • Shaperon

  • Sienna Biopharma

  • Sterna Biologicals

  • Therapeutics

  • Tioga

  • Valeant

  • Vanda Pharma

  • XBiotech

  • Xencor

  • Ziarco Pharma